ACLASTA SOLUTION
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
13-12-2022
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)
Disponible des:
SANDOZ CANADA INCORPORATED
Codi ATC:
M05BA08
Designació comuna internacional (DCI):
ZOLEDRONIC ACID
Dosis:
5MG
formulario farmacéutico:
SOLUTION
Composición:
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 5MG
Vía de administración:
INTRAVENOUS
Unidades en paquete:
100ML
tipo de receta:
Prescription
Área terapéutica:
BONE RESORPTION INHIBITORS
Resumen del producto:
Active ingredient group (AIG) number: 0141761003; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2022-12-13
Fitxa tècnica
Page1 of 65
PRODUCT MONOGRAPH
Pr
ACLASTA
®
(zoledronicacid injection)
5mg/100mL solutionforintravenousinfusion
Bone MetabolismRegulator
SandozCanadaInc.
110 Rue deLauzon
Boucherville,Quebec
CanadaJ4B1E6
Control Number:269479
ACLASTAisaregisteredtrademark
DateofPreparation:
DEC 9,2022
Page2 of65
Table of Contents
PARTI:HEALTHPROFESSIONALINFORMATION..........................................................3
SUMMARYPRODUCTINFORMATION
........................................................................3
INDICATIONSAND CLINICALUSE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGSANDPRECAUTIONS..................................................................................4
ADVERSE
REACTIONS..................................................................................................11
DRUGINTERACTIONS
..................................................................................................25
DOSAGEAND ADMINISTRATION
..............................................................................27
OVERDOSAGE
................................................................................................................29
ACTIONANDCLINICAL PHARMACOLOGY
............................................................29
STORAGE ANDSTABILITY
..........................................................................................32
SPECIALHANDLINGINSTRUCTIONS
.......................................................................33
DOSAGEFORMS,COMPOSITIONAND PACKAGING
.............................................33
PARTII:SCIENTIFICINFORMATION
...............................................................................34
PHARMACEUTICAL
INFORMATION..........................................................................34
CLINICALTRIALS
..........................................................................................................34
DETAI
Llegiu el document complet
